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Extensive research is currently being conducted into metal complexes that can selectively deliver
cytotoxins to hypoxic regions in tumours. The development of pharmacologically suitable agents requires
an understanding of appropriate ligand–metal systems for chaperoning cytotoxins. In this study, cobalt
complexes with tripodal tren (tris-(2-aminoethyl)amine) and tpa (tris-(2-pyridylmethyl)amine) ligands
were prepared with ancillary hydroxamic acid, β-diketone and catechol ligands and several parameters,
including: pKa, reduction potential and cytotoxicity were investigated. Fluorescence studies demonstrated
that only tpa complexes with β-diketones showed any reduction by ascorbate in situ and similarly, cellular
cytotoxicity results demonstrated that ligation to cobalt masked the cytotoxicity of the ancillary groups in
all complexes except the tpa diketone derivative [Co(naac)tpa](ClO4)2 (naac = 1-methyl-3-(2-naphthyl)-
propane-1,3-dione). Additionally, it was shown that the hydroxamic acid complexes could be isolated in
both the hydroxamate and hydroximate form and the pKa values (5.3–8.5) reveal that the reversible
protonation/deprotonation of the complexes occurs at physiologically relevant pHs. These results have
clear implications for the future design of prodrugs using cobalt moieties as chaperones, providing a basis
for the design of cobalt complexes that are both more readily reduced and more readily taken up by cells
in hypoxic and acidic environments.
Introduction
The remodelling of the vascular system that occurs under
hypoxia is intrinsically linked to the progression of many dis-
eases including stroke, ischemic heart disease, peripheral vascu-
lar disease, anaerobic infection and, importantly, cancer.1 Indeed,
hypoxia occurs to a variable extent in most tumours.2 Its promi-
nence in cancer is attributable to interrupted, or absent, endo-
thelial linings and the impaired vascularisation that occur as a
result of uncontrolled cell proliferation.3
Hypoxia in tumours is generally associated with a poor treat-
ment prognosis. In chemotherapy, hypoxic cells are less suscep-
tible to traditional drugs because of the growth arrested state,4
limited drug penetration5 and induced resistance mechanisms of
such cells.6 Similarly, radiotherapy agents are far less effective in
regions of hypoxia,7 mainly because oxygen is required to
convert the initial free radicals formed by ionisation into DNA
strand breaks.8
However, while tumoural hypoxia has been seen as an impedi-
ment to therapy, it has been suggested that it could be exploited
as a target for selective activation of prodrugs. One of the diffi-
culties associated with chemotherapy is that cancer cells, unlike
bacteria and viruses, do not have molecular targets that are com-
pletely foreign to the host which has limited the usefulness of
some chemotherapeutic agents due to toxic side-effects.4 For this
reason differences between tumours and healthy tissue such as
pH,9 tumour-specific enzymes,10 tumour-specific antigens,4,11
hypoxia12 and combinations of these13 have been explored as
potential targets.
3-Aminobenzotriazine-1,4-di-N-oxide or tirapazamine (TPZ)
is one of the most well known biologically active aromatic
N-oxides and has shown one of the largest differential toxicities
between hypoxic and normoxic cells for any hypoxia-activated
prodrug, with hypoxic cell response (HCR) values between 50
and 300 for a variety of different cell lines.14 Other hypoxia-
selective drugs include aliphatic N-oxides,15 quinones,16
nitroaromatics,17 and metal complexes.18 Cobalt complexes are
of particular interest as hypoxia selective prodrugs because of
the marked difference in lability between the higher (III) and
lower (II) oxidation states of cobalt. Ware and co-workers have
examined a number of cobalt complexes bearing acetylacetone-
derived ancillary ligands with monodentate,19 bidentate20 and tri-
dentate nitrogen mustards.21 A number of different nitrogen
mustard complexes with alternate ancillary ligands including
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dialkyldithiocarbamate,22 tropolonate,23 carbonato,18 oxalate
groups18 as well as cyclen derivatives with hydroxyquinolines24
and tpa complexes with hydroxamic acids have been
investigated.25
At this stage however, it is not known whether the biologically
relevant behaviour of these complexes is exclusively limited to
certain ligand systems and the relationships between charge,
pKa, lipophilicity and reduction potential are just being un-
ravelled.26,27 The purpose of this study is to examine a variety of
cobalt complexes with tripodal ligands and different bidentate
oxygen co-ligands to ascertain which systems are likely to be the
most biologically effective.
Experimental
Materials
All solvents used were laboratory grade and were used without
further purification unless otherwise stated. CoCl2·6H2O and
ethane-1,2-diamine were obtained from Merck. Hydrogen per-
oxide (30%, v/v) was obtained from Ajax chemicals. All other
chemicals were purchased from Sigma Aldrich. C25 Sephadex
(bead size 40–120 μM) was used for cation exchange chromato-
graphy (column dimensions are given as diameter × height).
Caution! Many of the procedures involved the preparation of
perchlorate salts of metal complexes. While no issues were
experienced with these compounds, such compounds should
also be handled with care as they are potentially hazardous. Par-
ticular care was taken with the tris(2-methylpyridyl)amine per-
chlorate (tpa·nHClO4) ligand as organic perchlorate molecules
are potentially explosive.
DLD-1 human colon carcinoma cells were obtained from
ATCC and used within 6 months of resuscitation. Cells were
maintained in Advanced DMEM (Invitrogen) and supplemented
with 2% FBS and 2 mM glutamine in a humidified environment
at 37 °C and 5% CO2.
Instrumentation
Microanalysis (C, H, N) was conducted by Chemical & Micro-
Analytical Services Pty Ltd or the Campbell Microanalytical
Laboratory, Department of Chemistry at the University of Otago.
1H and 13C NMR spectra were collected at 300 K on a Bruker
300 MHz spectrometer using commercially available deuterated
solvents. TSP (sodium (3-(trimethylsilyl)propionate)) was used
as an internal reference in D2O. In all other solvents isotopic
impurities were used as internal reference signals.28
The mass spectrometry was performed using Electro-Spray
Ionisation on a Finnigan LCQ-8 spectrometer.
UV-visible measurements were performed on a Cary 1E UV-
visible spectrophotometer using a 1 cm × 1 cm quartz cuvette.
Solutions for pH titrations for hydroxamic acid derivatives were
performed at approximately 1 mM in DMF–water (1 : 1) with
20 mM buffer (citrate/phosphate/triethylamine).
Fluorescence measurements were performed on a LS 50 B
luminescence spectrometer using a 1 cm × 1 cm silica cuvette.
Scans were run as 2.0 × 10−5 M solutions in methanol–water
(1 : 1) at 100 nm min−1. The relative fluorescence intensities
were calculated by comparing the areas under the emission
spectra. Emission spectra for naphthalene hydroxamic acid and
catechol compounds were run between 300 and 500 nm with
excitation at 280 nm, while β-diketone complexes were run at
380–600 nm with excitation at 350 nm.
Ascorbic acid reduction studies were performed on 1.0 × 10−5
M solutions of complexes in phosphate-buffered (0.1 mM)
methanol–water (1 : 1) over 24 hours after the addition of
ascorbic acid (20 equivalents). Complexes used in the reduction
study were: [Co(cat)tpa]·ClO4, [Co(cat)tren]·ClO4, [Co(nha-H)-
tpa]·ClO4, [Co(nha-H)tren]·ClO4, [Co(naac)tpa]·(ClO4)2 and
[Co(naac)tren]·(ClO4)2. The equipment and set up used was the
same as described for the fluorescence experimentation. The pH
of solution in all cases was 7.0.
Electrochemistry was performed on a BAS100B instrument
using a glassy carbon working electrode, a silver/silver chloride
reference electrode and a platinum auxiliary electrode. Scans
were performed at a scan rate of 100 mV s−1 unless otherwise
stated and the solutions were degassed with argon for at least ten
minutes prior to scanning. All experiments were performed at
room temperature and were iR compensated. Scans done in
DMF and DMF–water (4 : 1) were performed with 0.1 M tetra-
butylammonium perchlorate (TBAP) as the supporting electro-
lyte and the ferrocene/ferrocenium couple was used as an
internal reference. Aqueous scans were performed with sodium
perchlorate (0.1 M) as the supporting electrolyte and were refer-
enced to the Ag/AgCl couple.
Crystallography
Data were collected to approximately 56° 2θ using either a
Bruker SMART 1000 diffractometer employing graphite-mono-
chromated Mo-Kα radiation generated from a sealed tube
(0.71073 Å)29 or a Bruker–Nonius APEX2-X8-FR591 diffracto-
meter employing graphite-monochromated Mo-Kα radiation
generated from a rotating anode (0.71073 Å).30 Data integration
and reduction were undertaken with either teXsan,31 or SAINT
and XPREP.29,30 Subsequent computations were carried out
using either teXsan31 or the WinGX-32 graphical user inter-
face.32 Structures were solved by direct methods using
SHELXS-8634 or SIR97.54 Multi-scan empirical absorption cor-
rections, when applied, were applied to the data set using the
program SADABS.33 Data were refined and extended with
SHELXL-93 or SHELXL-97.34 In general, non-hydrogen atoms
with occupancies greater than 0.5 were refined anisotropically.
Carbon-bound hydrogen atoms were included in idealised pos-
itions and refined using a riding model. Oxygen and nitrogen
bound hydrogen atoms were first located in the difference
Fourier map before refinement with bond length restraints.
Where these hydrogen atoms could not be located, they were not
modelled. Disorder was modelled using standard crystallo-
graphic methods including constraints and restraints where
necessary. Structural data are summarised in Table 1 and specific
details (where necessary) pertaining to the refinement is given
below.
[Co(naac)tren]·0.5H2O·2ClO4. Two of the perchlorate anions
in the structure are disordered and modelled each over two posi-
tions with occupancies of 0.875 and 0.125 respectively.
11294 | Dalton Trans., 2012, 41, 11293–11304 This journal is © The Royal Society of Chemistry 2012
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Table 1 Crystallographic data
Compound
[Co(naac)tren]·
0.5H2O·2ClO4
[Co(bha)tren]·
2ClO4
[Co(aha)tren]·
2ClO4
[Co(bzac)tren]·
0.6I·1.4ClO4
[Co(acac)tren]·
2H2O·2Cl
[Co(nha)tren]·
2ClO4
Formula of
refinement model
C80H121Cl8Co4
N16O42.50
C13H24Cl2
CoN5O10
C8H22Cl2
CoN5O10
C16H27C11.4
CoI0.6N4O7.6
C11H25Cl2
CoN4O4
C18H28Cl2
CoN5O10
Molecular weight 2506.25 540.20 478.13 581.72 407.18 604.28
Crystal system Monoclinic Orthorhombic Triclinic Orthorhombic Triclinic Monoclinic
Space group P21/c P212121 P1ˉ P212121 P1 P21/n
a (Å) 13.3978(8) 9.1320(6) 8.455(3) 10.139(2) 7.779(3) 8.2091(3)
b (Å) 28.7543(18) 13.5840(9) 9.447(3) 14.370(3) 7.864(3) 16.7587(7)
c (Å) 26.4339(17) 16.711(1) 12.232(4) 15.118(3) 8.045(3) 17.1486(7)
α (°) 98.584(6) 100.627(6)
β (°) 93.677(4) 101.007(6) 106.855(6) 93.560(2)
γ (°) 112.488(6) 102.071(6)
V (Å3) 10162.5(11) 2073.0(2) 859.2(5) 2202.7(8) 444.5(3) 2354.65(16)
Dc (g cm
−3) 1.638 1.731 1.848 1.754 1.521 1.705
Z 4 4 2 4 1 4
Crystal size (mm) 0.28 × 0.20
× 0.20
0.2 × 0.2
× 0.1
0.2 × 0.2
× 0.02
0.32 × 0.19
× 0.15
0.339 × 0.255
× 0.129
0.30 × 0.28
× 0.25
Crystal colour Red Red Red Red Red Red
Crystal habit Block Prism Plate Prism Plate Block
Temperature (K) 150(2) 273(2) 273(2) 150(2) 150(2) 150(2)
λ(MoKα) 0.71073 0.71073 0.71073 0.71073 0.71073 0.71073
μ (mm−1) 0.951 1.149 1.372 1.838 1.286 1.022
T(Empirical)min,max 0.766, 0.827 0.8046, 0.9015 0.283766,
1.000000
0.649, 0.759 N/A 0.6688, 0.7457
2θmax (°) 63.60 56.02 55.88 56.74 55.90 60.00
hkl range −19 to 18, −42 to
42, −39 to 39
−12 to 12, 0 to
17, 0 to 22
−11 to 10, −12
to 12, 0 to 16
−13 to 13, −18 to
18, −20 to 19
−10 to 10, −10 to
10, −10 to 10
−11 to 11, −23 to
23, −24 to 23
Nobs (Nvar) 218 559 (1507) 4887 (280) 2975 (235) 22 247 (308) 4102 (212) 38 930 (325)
Nind (Rmerge) 34 567 (0.0320) 2802 (N/A) 3992 (N/A) 5347 (0.0383) 3778 (0.0640) 6851 (0.0477)
Nobs – (I > 2σ(I)) 23 279 4569 2097 4869 3772 5628
R1 – (I > 2σ(I)),
wR2 – (all)
0.0346, 0.1054 0.0425, 0.1219 0.0720, N/A 0.0308, 0.0777 0.0557, 0.1505 0.0335, 0.1215
GoF 1.038 1.048 2.510 1.051 1.054 1.132
Residual
extrema/e− Å−3
−0.480, 0.628 −0.372, 1.082 −1.26, 1.48 −0.331, 0.609 −0.940, 0.769 −0.619, 0.648
Compound
[Co(Clacac)tpa]·
0.5H2O·2ClO4
[Co(nha-H)tpa]·
EtOH·2H2O·ClO4
[Co(bzac)tpa]·
2ClO4,
[Co(cat)tpa]·
ClO4
[Co(naac)tpa]·
2ClO4
[Co(acac)tpa]·
H2O·2ClO4
Formula of refinement
model
C46H50Cl6
Co2N8O21
C3H30
ClCoN5O9
C28H27Cl2
CoN4O10
C56H48Cl2
Co2N8O12
C32H29Cl2
CoN4O10
C23H27Cl2
CoN4O11
Molecular weight 1381.50 710.98 709.37 1213.78 759.42 665.32
Crystal system Monoclinic Orthorhombic Monoclinic Monoclinic Monoclinic Triclinic
Space group Cc P21212 P21/n P21/c P21/n P21/c
a (Å) 17.281(6) 14.729(5) 12.011(2) 21.553(3) 12.836(5) 15.9070(8)
b (Å) 17.298(6) 23.560(8) 18.474(3) 10.8220(14) 17.758(7) 8.9780(4)
c (Å) 18.867(6) 9.935(3) 13.884(3) 22.239(3) 14.707(6) 19.1400(9)
α (°)
β (°) 90.172(7) 106.166(6) 93.066(9) 104.636(7) 97.115(3)
γ (°)
V (Å3) 5640(3) 3447.4(19) 2958.9(9) 5179.7(12) 3244(2) 2712.4(2)
Dc (g cm
−3) 1.627 1.370 1.592 1.556 1.555 1.629
Z 4 4 4 4 4 4
Crystal size (mm) 0.46 × 0.31
× 0.25
0.50 × 0.26
× 0.24
0.28 × 0.20
× 0.13
0.2 × 0.15
× 0.10
0.345 × 0.267
× 0.198
0.30 × 0.25
× 0.20
Crystal colour Red Green Red Green Red Red
Crystal habit Prism Prism Prism Plate Prism Block
Temperature (K) 150(2) 150(2) 90(2) 150(2) 150(2) 90(2)
λ(MoKα) 0.71073 0.71073 0.71073 0.71073 0.71073 0.71073
μ (mm−1) 0.957 0.633 0.826 0.818 0.759 0.897
T(Empirical)min,max 0.670, 0.787 0.853, 1.000 0.6793, 0.7458 0.6688, 0.7457 0.737, 1.00 0.6640, 0.7460
2θmax (°) 56.70 56.60 57.44 50.00 56.16 60.10
hkl range −23 to 22, −22 to
23, −25 to 24
−19 to 19, −31 to
31, −13 to 13
−16 to 16, −24
to 24, −18 to 18
−25 to 25, −12
to 12, −26 to 26
−16 to 16, −23
to 22, −19 to 19
−22 to 22, −12
to 12, −26 to 26
Nobs (Nvar) 27 035 (835) 34 314 (352) 26 163 (407) 52 547 (721) 31 644 (443) 30 220 (378)
Nind (Rmerge) 13 195(0.0736) 8350 (0.0273) 7646 (0.0711) 9100 (0.1921) 7718 (0.0813) 7922 (0.0536)
Nobs – (I > 2σ(I)) 12 072 7494 5192 4288 5676 6203
R1 – (I > 2σ(I)), wR2 – (all) 0.0836, 0.2292 0.0656, 0.1651 0.0516, 0.1453 0.0635, 0.1303 0.0407, 0.0995 0.0420, 0.1189
GoF 1.014 1.393 1.033 0.937 1.205 1.028
Residual extrema/e− Å−3 −0.589, 0.756 −0.557, 0.980 −0.524, 0.905 −0.647, 0.744 −0.459, 0.663 −0.727, 1.113
This journal is © The Royal Society of Chemistry 2012 Dalton Trans., 2012, 41, 11293–11304 | 11295
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[Co(acac)tren]·2H2O·2Cl. This data set proved to be twinned
by a two-fold rotation about c. Accordingly no absorption cor-
rection was applied. The water-hydrogen atoms could not be
located in the difference Fourier map and were not modelled.
[Co(Clacac)tpa]·0.5H2O·2ClO4. The structure crystallised in
the monoclinic space group Cc with β very close to 90° (90.172(7)°)
and a and b approximately equal, proving to be a twin emulating
tetragonal symmetry with an additional general twining
component. The twinning was accounted for by the use of the
appropriate twin law35 resulting in a significant decrease in the R
factor. In addition, one of the two complexes in the asymmetric
unit is rotationally disordered and was modelled over two pos-
itions with occupancies of 0.75 and 0.25. The thermal par-
ameters of the lower occupancy component were refined
isotropically with a shared value. Two of the perchlorate anions
are also modelled over two positions with a total occupancy of 1
each. The water-hydrogen atoms could not be located in the
difference Fourier map and were not modelled.
[Co(nha-H)tpa]·EtOH·2H2O·ClO4. The napthalene group,
water solvents and perchlorate anions are all disordered.
[Co(cat)tpa]·ClO4. One of the perchlorate anions is disordered
and modelled over two positions.
Cytotoxicity studies
IC50 values were determined by seeding 1 × 10
5 cells per mL
into each well of a 96-well plate and incubating under standard
culturing conditions. Compounds were prepared as 5 mM solu-
tions in 10% DMSO except [Co(naac)tpa](ClO4)2 and [Co-
(naac)tren](ClO4)2 which were prepared as 5 mM solutions in
20% DMSO. naacH was prepared as a 13 mM solution in 75%
DMSO, and catH2 was prepared as a 5 mM solution in 50%
DMSO solution prior to the assay. Concentrated drug samples
were prepared to ensure the solvent systems were not toxic to the
DLD-1 cells. All solutions were then filtered through a 0.25 mm
Millex Syringe Filters (Millipore). The dose volume of the com-
pound solutions was kept below 40 μL and diluted in culture
medium to be added to triplicate wells, spanning a 4-log range
of final concentrations. The cells were then incubated for
72 hours before 1.0 mM MTT was added to each well and
further incubated for 4 hours. The media was removed and
150 μL of DMSO was added to each well. The absorbance of
each well was then measured at 600 nm after shaking for 1 min
in a Victor3V microplate reader (Perkin-Elmer). IC50 values were
determined as the compound concentration that reduced the
absorbance to 50% of that in untreated control wells.
Synthesis
[CoCl2tren]Cl·H2O,
36 [CoCO3tren]ClO4·0.5H2O,
36 tpa·nHClO4,
37
[Co(NO2)2tpa]ClO4,
37 [CoCl2tpa]ClO4,
38 [Co(aha-H)tpa]ClO4,
25
[Co(bha-H)tpa]ClO4
25 and 1-methyl-3-(2-naphthyl)propane-1,3-
dione (naacH),39 were all synthesised using published exper-
imental procedures. Methyl-2-(naphthalen-1-yl)acetate was pre-
pared from 2-(naphthalen-1-yl)acetic acid using standard
esterification techniques. A schematic diagram of the ligands
used in this study is shown in Fig. 1.
[Co(acac)tpa](ClO4)2. Acetylacetone (acacH) (1.4 mmol,
140 mg, 136 μL) was added to a dispersion of [CoCl2tpa]ClO4
(520 mg, 1.0 mmol) in methanol (5.0 mL). After 5 minutes, tri-
ethylamine (1.2 mmol, 120 mg, 170 μL) was added and the sol-
ution was refluxed for 1 hour at 50 °C. The solution was cooled
on an ice bath, diethyl ether (25 mL) was added and the precipi-
tate collected. The crude product was dispersed in an aqueous
NaClO4 solution (0.10 M, 5.0 mL) and acetone added until the
complete dissolution of the product. Slow evaporation of this
solution yielded red square crystals of [Co(acac)tpa](ClO4)2
(Yield: 52%, 337 mg, 0.52 mmol). Crystals suitable for X-ray
analysis were taken directly from this mixture. 1H NMR
(DMSO): δ 9.14 (d, H, pyridyl), 8.24 (d, 2H, pyridyl), 8.16 (t,
2H, pyridyl), 7.99 (t, H, pyridyl), 7.79 (d, 2H, pyridyl), 7.74 (t,
H, pyridyl), 7.60 (t, 2H, pyridyl), 7.40 (d, H, pyridyl), 5.88 (s,
1H, γ-hydrogen of acac), 5.54 (half of AB system, 2H, CH2N),
5.27 (s, 2H, CH2N), 5.03 (half of AB system, 2H, CH2N), 2.75
(s, 3H, CH3), 2.00 (s, 3H, CH3).
13C NMR (DMSO): δ 191.84,
191.64, 163.26, 162.22, 148.84, 147.09, 141.58, 140.94, 126.52,
125.97, 124.73, 122.24, 99.62, 69.78, 68.435, 27.33, 26.24.
Mass spec (ESI positive ion): m/z: 547 ([Co(acac)tpa](ClO4)
+),
224 ([Co(acac)tpa]2+). Anal. Required for CoH25C23N4O10Cl2:
C, 42.67, H, 3.89, N, 8.66%. Found: C, 42.63, H, 3.91, N,
8.71%.
[Co(Clacac)tpa](ClO4)2. [Co(Clacac)tpa](ClO4)2 (ClacacH =
3-chloro-2,4,-pentanedione) was synthesised in an analogous
manner to [Co(acac)tpa](ClO4)2 (Yield: 60%, 408 mg,
0.60 mmol). Slow evaporation of a solution of the product
yielded red square crystals of [Co(Clacac)tpa](ClO4)2 suitable
for X-ray analysis. 1H NMR (DMSO): δ 9.12 (d, H, pyridyl),
8.26 (d, 2H, pyridyl), 8.19 (t, 2H, pyridyl), 8.01 (t, H, pyridyl),
7.82 (d, 2H, pyridyl), 7.74 (t, H, pyridyl), 7.63 (t, 2H, pyridyl),
7.39 (d, H, pyridyl), 5.60 (half of AB system, 2H, CH2N), 5.25
(s, 2H, CH2N), 5.02 (half of AB system, 2H, CH2N), 2.99 (s,
3H, CH3), 2.27 (s, 3H, CH3).
13C NMR (DMSO): δ 189.45,
162.99, 162.78, 149.51, 146.76, 141.46, 140.77, 126.45, 125.82,
124.59, 122.08, 106.11, 69.58, 68.20, 28.14, 27.22. Mass spec
(ESI positive ion) m/z: 581 ([Co(Clacac)tpa](ClO4)
+), 241
([Co(Clacac)tpa]2+). Anal. Required for CoH24C23N4O10Cl3: C,
40.52, H, 3.55, N, 8.22%. Found: C, 40.41, H, 3.61, N, 8.25%.
Fig. 1 Ligands employed in this study.
11296 | Dalton Trans., 2012, 41, 11293–11304 This journal is © The Royal Society of Chemistry 2012
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[Co(bzac)tpa](ClO4)2. 1-Phenyl-1,3-butanedione (bzacH)
(1.4 mmol, 227 mg) was added to a dispersion of [CoCl2tpa]-
ClO4 (520 mg, 1.0 mmol) in methanol (5.0 mL). After
5 minutes, triethylamine (1.2 mmol, 121 mg, 170 μL) was added
and the solution was refluxed for 1 hour at 60 °C. The solution
was cooled on an ice bath and the precipitate was collected. The
crude product was washed several times with diethyl ether
before being dispersed in an aqueous NaClO4 solution (0.10 M,
5.0 mL). Acetone was added until complete dissolution of the
product was achieved. Slow evaporation of this solution yielded
red needles of [Co(bzac)tpa](ClO4)2 (Yield: 35%, 248 mg,
0.35 mmol). 1H NMR (DMSO): δ 9.20 (d, H, pyridyl), 8.33 (d,
2H, pyridyl), 8.14 (t, 2H, pyridyl), 8.03 (t, H, pyridyl), 7.87 (d,
2H, phenyl), 7.81–7.77 (m, 3H, pyridyl), 7.63–7.54 (m, 3H, (2H
pyridyl, H phenyl), 7.49–7.40 (m, 3H, (2H phenyl, 1H pyridyl))
5.60 (half of AB system, 2H, CH2N), 5.34 (s, 2H, CH2N), 5.14
(half of AB system, 2H, CH2N), 2.93 (s, 3H, CH3).
13C NMR
(DMSO): δ 194.44, 181.52, 163.35, 163.12, 149.78, 147.10,
141.60, 141.04, 134.32, 133.29, 128.85, 127.72, 126.62, 126.01,
124.96, 122.31, 96.60, 70.08, 68.60, 28.10. Mass spec (ESI
positive ion): m/z: 609 ([Co(bzac)tpa](ClO4)
+); 255 ([Co(bzac)-
tpa]2+). Anal. Required for CoH27C28N4O10Cl2: C, 47.41, H,
3.84, N, 7.90%. Found: C, 47.37, H, 3.96, N, 7.88%.
[Co(naac)tpa](ClO4)2. [Co(naac)tpa](ClO4)2 was synthesised
in an analogous manner to [Co(bzac)tpa](ClO4)2 (Yield: 42%,
319 mg, 0.42 mmol). Slow evaporation of an acetone–water solu-
tion containing the product yielded crystals suitable for X-ray
analysis. 1H NMR (DMSO): δ 9.24 (d, H, pyridyl), 8.52 (s, H,
naphthyl), 8.37 (d, 2H, pyridyl), 8.17–7.82 (m, 10H, (6H
pyridyl, 4H naphthyl)) 7.65–7.57 (m, 4H, (2H pyridyl, 2H
naphthyl)), 7.46 (d, H, pyridyl) 6.92 (s, 1H, γ-hydrogen of
acac), 5.72 (half of AB system, 2H, CH2N), 5.38 (s, 2H, CH2N),
5.21 (half of AB system, 2H, CH2N), 2.99 (3H, s, CH3).
13C
NMR (DMSO): δ 194.23, 181.45, 163.36, 163.18, 149.58,
147.14, 141.60, 141.05, 134.72, 131.97, 131.67, 129.58, 128.94,
128.76, 128.43, 127.41, 126.95, 126.62, 126.01, 125.00, 123.58,
122.31, 96.96, 70.09, 69.00, 28.20. Mass spec. (ESI positive
ion): m/z: 659 ([Co(naac)tpa](ClO4)
+); 280 ([Co(naac)tpa]2+).
Anal. Required for CoH29C32N4O10Cl2: C, 50.61, H, 3.85, N,
7.38%. Found: C, 50.68, H, 3.91, N, 7.43%.
[Co(acac)tren]Cl2·2H2O. [Co(acac)tren]Cl2·2H2O was pre-
pared by a modification of the procedure used for synthesising
[Co(acac)tren]I2 by Nakano et al.
40 [CoCl2tren]Cl·H2O (1.0 g,
3.0 mmol) was dissolved in water (20 mL) and acacH (480 mg,
495 μL, 4.8 mmol) added. After 10 minutes an aqueous sodium
hydroxide solution (1.0 M, 5.0 mL) was added and the solution
was stirred for 3 hours at 60 °C. After the mixture was cooled to
room temperature, water (75 mL) was added and the solution
was loaded onto a Sephadex column (Na+ form, 3.5 × 20 cm).
The column was washed with water and 0.01 M NaCl and the
product was eluted with 0.3 M NaCl. Once the excess salt was
removed (with considerable product loss), the compound was
dissolved in a minimal amount of water, and deep red crystals of
[Co(acac)tren]Cl2·2H2O were precipitated upon the slow diffu-
sion of ethanol (Yield: 48%, 616 mg 1.5 mmol). Crystals suit-
able for X-ray analysis were taken directly from this crop. 1H
NMR (D2O): δ 5.78 (s, 1H, γ-hydrogen of acac), 3.62 (td,
2H, tren), 3.44 (td, 2H, tren), 3.30 (t, 2H, tren), 3.14 (dd, 2H,
tren), 2.97 (t, 2H, tren), 2.79 (dd, 2H, tren), 2.23, (s, 3H, CH3 of
acac), 2.14, (s, 3H, CH3 of acac).
13C NMR (D2O): δ 195.45,
193.63, 101.58, 63.78, 63.32, 47.44, 45.87, 29.43, 28.95. Mass
spec (ESI positive ion): m/z: 152 ([Co(acac)tren]2+). Anal.
Required for CoH29C11N4O4Cl2: C, 32.13, H, 7.11, N, 13.63%.
Found: C, 32.07, H, 7.07, N, 13.70%.
[Co(bzac)tren]I2. [Co(bzac)tren]I2 was prepared by an adap-
tation of the procedure used for synthesising [Co(acac)tren]I2 by
Nakano et al.40 A mixture of [CoCO3tren]ClO4·0.5H2O (1.0 g,
2.7 mmol) in 2.5 M HCl (4 mL) and stirred for half an hour
until effervescence had ceased. BzacH (620 mg, 3.9 mmol) was
added to this solution followed by an aqueous sodium hydroxide
solution (0.50 M, 16 mL) and the mixture was stirred at 80 °C
for 3 hours. The solution was cooled to room temperature,
filtered, and solid KI was added to the filtrate until the precipi-
tation of orange/red [Co(bzac)tren]I2 was achieved. The product
was washed once with ethanol and several times with diethyl
ether before being recrystallised from water (Yield: 51%,
930 mg, 1.5 mmol). Crystals suitable for X-ray analysis were
formed by slow evaporation of the filtrate. 1H NMR (D2O): δ
7.99 (d, 2H, phenyl), 7.66 (t, H, phenyl), 7.55 (t, 2H, phenyl),
6.50 (s, 1H, γ-hydrogen of acac), 3.75, (td, 2H, tren), 3.50 (td,
2H, tren), 3.35 (t, 2H, tren), 3.16 (dd, 2H, tren), 2.97 (t, 2H,
tren), 2.89 (dd, 2H, tren) 2.30 (s, 3H, CH3 of acac)
13C NMR
(D2O): δ 197.86, 184.60, 138.83, 135.50, 131.62, 130.25, 98.67,
64.25, 63.53, 47.52, 45.98, 29.77. Mass spec (ESI positive ion):
m/z: 183 ([Co(bzac)tren]2+). Anal. Required for
CoH27C16N4O2I2: C, 30.99, H, 4.39, N, 9.04%. Found: C,
31.03, H, 4.42, N, 9.02%. [Co(bzac)tren](ClO4)2 could also be
prepared by a small modification of the above synthesis by
addition of dilute perchloric acid (0.1 M) instead of solid KI.
The NMR was as described for [Co(acacphen)tren]I2. Anal.
Required for CoH27C16N4O10Cl2: C, 34.00, H, 4.81, N, 9.91%.
Found: C, 34.02, H, 4.81, N, 9.72%.
[Co(naac)tren](ClO4)2. NaacH (1.0 g, 5.0 mmol) was added
to a dispersion of [CoCl2tren]Cl·H2O (1.0 g, 3.0 mmol) in
MeOH (40 mL). The solution was stirred for five minutes before
triethylamine (4.5 mmol) was added and the solution was
refluxed for 48 hours. The solution was dried over a nitrogen
line, water (100 mL) was added and the solution was filtered.
The filtrate was then loaded onto a Sephadex column, washed
with water, and the major product was eluted with 0.30 M
NaClO4. Slow evaporation of the eluent solution caused the pre-
cipitation of red crystals of [Co(naac)tren](ClO4)2. (Yield: 25%,
461 mg, 0.75 mmol) 1H NMR (D2O): δ 8.56 (s, 1H, naphthyl),
8.12–8.03 (m, 4H, naphthyl), 7.75–7.65 (m, 2H, naphthyl), 6.67
(s, 1H, γ-hydrogen of acac), 3.86 (td, 2H, tren), 3.56 (td, 2H,
tren), 3.39 (t, 2H, tren), 3.19 (dd, 2H, tren), 3.03 (t, 2H, tren),
2.95 (dd, 2H, tren), 2.32 (s, 3H, CH3).
13C NMR (D2O):
δ 197.79, 184.46, 137.74, 136.36, 135.15, 132.14, 131.46,
131.32, 131.13, 130.63, 130.11, 126.60, 98.99, 64.35, 63.56,
47.56, 46.00, 29.80. Mass spec (ESI positive ion): m/z: 515
([Co(naac)tren](ClO4)
+); 208 ([Co(naac)tren]2+). Anal. Required
for CoH29C20N4O10Cl2: C, 39.04, H, 4.75, N, 9.11%. Found: C,
38.94, H, 4.79, N, 8.98%.
This journal is © The Royal Society of Chemistry 2012 Dalton Trans., 2012, 41, 11293–11304 | 11297
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[Co(aha)tren](ClO4)2·H2O. Aqueous sodium hydroxide
(1.0 M, 3.5 mL) was added dropwise slowly to a solution of
acetohydroxamic acid (ahaH) (285 mg, 3.8 mmol) and [CoCl2-
tren]Cl·H2O (1.0 g, 3.0 mmol) in water (30 mL) and the mixture
stirred at 70 °C for 6 hours. The solution was cooled, the solvent
removed over nitrogen and ethanol (20 mL) added to the solid
residue. The solution was filtered and a saturated solution of
sodium perchlorate in ethanol was added to the filtrate. The
resulting precipitate was collected, washed with ethanol, isopro-
panol and diethyl ether (Yield: 48%, 688 mg, 1.4 mmol). Crys-
tals were grown from an ethanol–water solution of the product.
1H NMR (D2O): δ 3.45–3.30 (m, 4H, tren), 3.23–3.15 (m, 4H,
tren), 3.00–2.92 (m, 4H, tren), 2.05 (s, 3H, CH3).
13C NMR
(D2O): δ 173.13, 65.66, 62.97, 47.24, 46.21, 16.97. Mass spec
(ESI positive ion): m/z: 277 ([Co(aha-H)tren]+). Anal. Required
for CoH24C8N5O11Cl2: C, 19.37, H, 4.65, N, 14.01%. Found: C,
19.37, H, 4.88, N, 14.12%.
[Co(aha-H)tren](ClO4). [Co(aha-H)tren](ClO4) was syn-
thesised by dissolving [Co(aha)tren](ClO4)2·H2O (200 mg,
0.42 mmol) in ethanol (5 mL) and adding one and a half equiva-
lents of sodium hydroxide (1 M, 1.5 equivalents). The solution
was allowed to sit in a fridge overnight, over which time violet
crystals of [Co(aha-H)tren](ClO4) precipitated out of solution
(Yield: 52%, 82 mg, 0.22 mmol). NMR experiments performed
in DMSO confirmed the removal of the NH proton on the hydro-
xamic acid. The complex crystallised as two isomers in approxi-
mately 3 : 2 ratio. Major isomer: 1H NMR (D2O): δ 3.64–2.85
(m, 12 H, tren), δ 1.88 (s, 3H, CH3).
13C NMR (D2O): δ 168.15,
62.85, 59.12, 44.51, 43.90, 14.51. Minor isomer: 1H NMR
(D2O): 3.64–2.85 (m, 12 H, tren), 1.82 (s, 3H, CH3).
13C NMR
(D2O): 167.46, 62.68, 60.01, 44.12, 43.69, 14.19. Mass spec
(ESI positive ion): m/z: 277 ([Co(aha-H)tren]+).
[Co(bha-H)tren](ClO4). [Co(bha-H)tren](ClO4) was syn-
thesised by an adaptation of the procedure used for [Co(aha)tren]-
(ClO4)2 but with aqueous sodium hydroxide (1.0 M, 10 mL),
benzohydroxamic acid (bhaH) (520 mg, 3.8 mmol) and [CoCl2-
tren]Cl·H2O (1.0 g, 3.0 mmol) in water (30 mL). [Co(bha-H)tren]-
(ClO4) was collected as a purple solid (Yield: 64%, 840 mg,
1.9 mmol). The complex crystallised as two isomers in a ratio
approximately 3 : 2. Major isomer: 1H NMR (D2O): δ 7.92 (d,
2H, phenyl), 7.70 (m, 3H, phenyl), 3.91 (m, 2H, tren),
3.64–2.85 (m, 10 H, tren). 13C NMR (D2O): δ 128.65, 127.44,
126.10, 124.00, 59.51, 56.25, 42.32, 41.58. Minor isomer: 1H
NMR (D2O): δ 7.75 (d, 2H, phenyl, 7.70 (m, 3H, phenyl), 3.55
(m, 2H, tren) 3.64–2.85 (m, 10 H, tren). 13C NMR (D2O):
δ 128.62, 127.44, 126.31, 124.19, 59.99, 57.44, 42.18, 41.01.
The carbon resonances for the CvO quaternary carbon were not
observed in either isomer. Mass spec (ESI positive ion): m/z:
340 ([Co(bha-H)tren]+) Anal. Required for C13H23ClCoN5O6:
C, 35.51, H, 5.27, N, 15.93%. Found: C, 35.42, H, 5.27,
N, 15.80%.
[Co(bha)tren](ClO4)2. [Co(bha)tren](ClO4)2 was synthesised
by dispersing [Co(bha-H)tren](ClO4) (200 mg, 0.46 mmol) in
water (5.0 mL) and adding 1.1 equivalents of perchloric acid
(0.1 M). The solution was allowed to sit in a fridge overnight,
over which time violet crystals of [Co(bha)tren](ClO4) precipi-
tated (Yield: 55%, 135 mg, 0.25 mmol). NMR experiments
performed in DMSO confirmed the appearance of the NH proton
on the hydroxamic acid at approximately 12.0 ppm. 1H NMR
(D2O): δ 7.78 (t, 2H, phenyl), 7.68 (t, H, phenyl), 7.57 (t, 2H,
phenyl), 3.48 (m, 4H, tren), 3.25 (m, 4H, tren), 3.03 (m, 4H,
tren). 13C NMR (D2O): δ 169.78, 133.05, 129.46, 127.09,
126.30, 63.30, 60.00, 44.86, 43.84. Mass spec (ESI positive
ion): m/z: 439 ([Co(bha)tren]ClO4
+); 340 ([Co(bha-H)tren]+);
170 ([Co(bha)tren]2+).
2-(Naphthalen-1-yl)hydroxamic acid. A suspension of hydro-
xylammonium chloride (10 g, 0.14 mol) in MeOH (10 mL) was
added dropwise to a solution of KOH (12 g, 0.21 mol) in water
(20 mL), with the temperature kept below 5 °C using an ice
bath. The solution was filtered and the filtrate was added to a sol-
ution of methyl-2-(naphthalen-1-yl)acetate (3.0 g, 15 mmol) in
methanol (10 mL) and stirred for 4 hours at 5 °C. The volume
was reduced to 20 mL over a stream of nitrogen before concen-
trated HCl was added dropwise until the formation of nhaH was
apparent as a white precipitate. This was collected at the pump,
washed with generous amounts of water and diethyl ether, and
dried under vacuum (Yield: 78%, 2.75 g, 11.7 mmol). 1H NMR
(MeOD): δ 8.04 (d, H, naphthyl), 7.73–7.62 (m, 2H, naphthyl),
7.55–7.42 (m, 4H, naphthyl), 3.91 (s, 2H, CH2).
13C NMR
(MeOD): δ 170.86, 135.30, 133.74, 132.25, 129.66, 128.87,
127.25, 126.77, 126.50, 124.73, 38.11. Mass spec (ESI positive
ion): m/z: 224 ([nhaH + Na]+). Mass spec (ESI negative ion):
m/z: 200 ([nha]−). Anal. Required for H11C12NO2: C, 71.62, H,
5.51, N, 6.96%. Found: C, 71.74, H, 5.61, N, 6.94%.
[Co(nha-H)tpa]ClO4·H2O. Aqueous sodium hydroxide
(1.0 M, 2.5 mL) was added dropwise to a dispersion of
[CoCl2tpa]ClO4 (520 mg, 1 mmol) and nhaH (240 mg,
1.2 mmol) in methanol (40 mL). After 1 hour the solution was
reduced in volume to approximately 30 mL, water was added
(200 mL), the was solution filtered and the filtrate was loaded
onto a Sephadex column (Na+ form, 3.5 × 20 cm). The column
was washed with water and the major green band eluted with
0.1 M NaCl. The eluent was reduced in volume over a nitrogen
line, a few drops of saturated NaClO4 solution were added and
the solution was left to stand in the refrigerator overnight. The
resulting precipitate of [Co(nha-H)tpa]ClO4·H2O was collected,
washed with water and diethyl ether and air dried (Yield: 30%,
200 mg, 0.3 mmol). The complex crystallised as two isomers in
1 : 1 ratio. Crystals suitable for X-ray diffraction were prepared
by slow evaporation of an ethanol–water (95 : 5) solution con-
taining the product. 1H NMR (DMSO): δ 9.07 (d, H, pyridyl),
9.02 (d, H, pyridyl), 8.48 (d, 2H, pyridyl), 8.39 (d, H, pyridyl),
7.99–7.74 (m, 10H), 7.56–7.26 (m, 19H), 6.97 (t, 3H) 6.56 (d,
H), 6.46 (d, H, pyridyl), 5.19–4.88 (m, 12H, CH2N), 4.06 (s,
2H, CH2CONH) 3.58 (s, 2H, CH2CONH).
13C NMR (DMSO):
δ 162.98, 162.48, 162.24, 161.62, 161.49, 149.34, 149.25,
149.15, 147.63, 139.65, 139.50, 139.30, 135.43, 134.90, 133.29,
132.25, 132.06, 131.35, 128.24, 128.00, 127.44, 126.78, 126.01,
125.54, 125.36, 125.20, 125.06, 124.90, 124.74, 124.19, 123.89,
123.05, 122.89, 121.27, 68.91, 68.54, 68.04, 67.72, 32.81,
31.76. Mass spec (ESI positive ion): m/z: 548 ([Co(nha-H)tpa]+).
Anal. Required for CoH29C30N5O7Cl: C, 54.10, H, 4.39, N,
10.52%. Found: C, 53.98, H, 4.47, N, 10.50%.
11298 | Dalton Trans., 2012, 41, 11293–11304 This journal is © The Royal Society of Chemistry 2012
Pu
bl
ish
ed
 o
n 
28
 Ju
ne
 2
01
2.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f Q
ue
en
sla
nd
 on
 12
/10
/20
15
 01
:48
:16
. 
View Article Online
[Co(nha)tpa](ClO4)2. [Co(nha)tpa](ClO4)2 was synthesised by
dispersing [Co(nha-H)tpa](ClO4) (200 mg, 0.31 mmol) in
ethanol–water (4 : 1, 5 mL) and adding 1.1 equivalents of per-
chloric acid (0.1 M). The volume was reduced until the desired
complex first precipitated, at which point the solution was
allowed to sit in a fridge overnight, over which time violet crys-
tals of [Co(nha)tren](ClO4) precipitated out of solution (Yield:
75%, 173 mg, 0.23 mmol). The complex crystallised as two
isomers in 5 : 2 ratio. NMR experiments performed in DMSO
confirmed the appearance of the NH proton on the hydroxamic
acid at approximately 12.5 ppm. Major isomer: 1H NMR
(DMSO): δ 13.20 (s, NH), 8.60 (d, H, pyridyl), 8.45 (d, 2H,
pyridyl), 8.10–7.20 (m, 16H, pyridyl and naphthyl), 5.19–4.95
(m, 6H, CH2N), 3.96 (s, 2H, CH2CONH). Minor Isomer:
1H
NMR (DMSO): 13.20 (s, NH), 8.85 (d, H, pyridyl), 8.45 (d, 2H,
pyridyl), 8.10–7.20 (m, 16H, pyridyl and naphthyl), 5.19–4.95
(m, 6H, CH2N), 4.50 (s, 2H, CH2CONH).
13C NMR (D2O):
δ 170.45, 170.40, 163.98, 163.24, 162.88, 159.85, 149.30,
148.91, 148.75, 148.28, 141.50, 141.12, 141.00, 139.84, 133.49,
133.45, 131.82, 131.39, 131.01, 131.40, 128.88, 128.03, 126.98,
126.90, 126.81, 126.74, 126.69, 126.61, 126.51, 126.39, 126.19,
126.08, 125.54, 124.92, 124.30, 123.67, 122.60, 69.81, 69.65,
69.24, 69.18, 32.85, 31.96. Mass spec (ESI positive ion): m/z
548 ([Co(nha)tpa]+); 274 ([Co(nha)tpa]2+).
[Co(nha-H)tren]ClO4·H2O. [Co(nha-H)tren]ClO4·H2O was
prepared using a derivation of the synthesis of [Co(nha-H)tpa]-
ClO4·H2O described above. Aqueous sodium hydroxide (1.0 M,
6.0 mL) was added dropwise to a dispersion of [CoCl2tren]-
Cl·H2O (660 mg, 2 mmol) and nhaH (500 mg, 2.5 mmol) in
methanol (150 mL). After 24 hours the solution was reduced in
volume to approx 30 mL, water (100 mL) was added, the sol-
ution was filtered and the filtrate was loaded onto a Sephadex
column (Na+ form, 3.5 × 20 cm). The column was washed with
water and the major maroon band was eluted with 0.2 M
NaClO4. Small crystals of [Co(nha-H)tren]ClO4·H2O formed
upon slow evaporation of the eluent. (Yield: 42%, 436 mg,
0.84 mmol) 1H NMR (D2O): δ 8.13 (d, 1H, naphthyl), 8.00 (d,
1H, naphthyl), 7.92 (d, 1H, naphthyl), 7.67–7.47 (m, 4H,
naphthyl), 4.01 (s, 2H, CH2CONH), 3.64–2.85 (m, 12H, tren).
13C NMR (D2O): δ 171.70, 136.39, 136.01, 134.51, 131.70,
130.54, 129.40, 129.19, 128.71, 127.10, 126.28, 65.09, 62.56,
47.09, 45.87, 35.35. Mass spec (ESI positive ion): m/z: 404 ([Co-
(nha-H)tren]+). Anal. Required for CoH29C18N5O7Cl: C, 41.43,
H, 5.60, N, 13.42%. Found: C, 41.41, H, 5.75, N, 13.41%.
[Co(nha)tren](ClO4)2. [Co(nha)tren](ClO4)2 was synthesised
by dispersing [Co(nha-H)tren](ClO4) (200 mg, 0.39 mmol) in
ethanol (5.0 mL) and adding one equivalent of perchloric acid
(0.10 M). The volume was reduced until the desired complex
first precipitated, at which point the solution was allowed to sit
in a fridge overnight, over which time red crystals of [Co(nha)-
tren](ClO4)2 precipitated out of solution (Yield: 68%, 163 mg,
0.27 mmol). The complex crystallised as two isomers in a 1 : 1
ratio. NMR experiments performed in DMSO confirmed the
appearance of the NH proton on the hydroxamic acid at approxi-
mately 13.1 ppm. 1H NMR (D2O): δ 8.28 (d, 1H, naphthyl),
8.10–7.91 (m, 4H, napthyl), 7.72–7.50 (m, 9H, napthyl), 4.27
(s, 2H, CH2), 4.21 (s, 2H, CH2), 3.41–2.75 (m, 24H, tren).
13C NMR (D2O): δ 174.14, 172.32, 136.09, 135.99, 134.01,
133.83, 131.97, 131.93, 131.50, 131.33, 131.04, 130.91, 130.85,
129.41, 129.10, 128.89, 128.29, 128.20, 126.34, 125.48, 65.08,
64.23, 62.41, 61.60, 46.75, 46.09, 45.97, 45.87, 34.85, 34.79.
Mass spec (ESI positive ion): m/z: No ions observed.
[Co(cat)tpa]ClO4. 2,3-Napthyldiol (catH2) (1.2 mmol,
190 mg) was added to a dispersion of [CoCl2tpa]ClO4 (520 mg,
1.0 mmol) in methanol (5.0 mL). After 5 minutes, triethylamine
(2.4 mmol, 242 mg, 340 μL) was added and the solution was
refluxed for 1 hour at 60 °C. The solution was cooled on an ice
bath, diethyl ether added and the precipitate was collected. The
crude product was washed several times with diethyl ether
before being dispersed in an aqueous NaClO4 solution (0.10 M,
5.0 mL). Acetone was added until complete dissolution of the
product was achieved. Slow evaporation of this solution yielded
green needles of [Co(cat)tpa]ClO4 (Yield: 82%, 500 mg,
0.82 mmol). Crystals suitable for X-ray diffraction were taken
directly from this mixture. 1H NMR (DMSO): δ 9.31 (d, H,
pyridyl), 8.43 (d, 2H, pyridyl), 8.00 (m, 3H, pyridyl, napthyl),
7.70 (m, 3H, pyridyl, naphthyl), 7.47 (t, 2H, pyridyl), 7.40 (t,
2H, pyridyl), 7.25 (s, H, napthyl), 7.17 (d, H, pyridyl), 6.90, (m,
2H, naphthyl), 6.47 (s, H, naphthyl), 5.43, (d, 2H, CH2,), 5.15
(m, 4H, CH2 × 2).
13C NMR (DMSO): δ 163.91, 163.83,
163.74, 165.02, 151.71, 149.49, 141.20, 141.82, 129.75, 129.54,
126.59, 126.28, 125.01, 124.89, 124.58, 122.47, 121.28, 121.26,
109.77, 108.92, 69.97, 69.48. Mass spec (ESI positive ion): m/z:
507 ([Co(cat)tpa]+). Anal. Required for C28H24ClCoN4O6: C,
55.41, H, 3.99, N, 9.23%. Found: C, 55.36, H, 4.03, N, 9.21%.
[Co(cat)tren]ClO4·1.5H2O. catH2 (1.2 mmol, 190 mg) in
MeOH (20 mL) was added to a solution of [CoCl2tren]Cl
(330 mg, 1.0 mmol) in water (5 mL). After 5 minutes, triethyl-
amine (2.4 mmol, 242 mg, 340 μL) was added and the solution
was stirred at room temperature. After 24 hours the solution was
reduced in volume to approx 5 mL, water (100 mL) was added,
the solution was filtered and the filtrate was loaded onto a Sepha-
dex column (Na+ form, 3.5 × 20 cm). The column was washed
with water and the major maroon band was eluted with 0.20 M
NaClO4. Small crystals of [Co(cat)tren]ClO4·H2O formed upon
slow evaporation of the eluent. (Yield: 36%, 130 mg,
0.36 mmol). 1H NMR (DMSO): δ 7.30 (m, 2H, naphthyl), 6.81,
(m, 3H, naphthyl) 6.65 (s, H, naphthyl), 4.99 (s, 2H, amine),
4.45 (s, 2H, amine), 3.98 (s, 2H, amine), 2.80 (m, 12H, tren).
13C NMR (DMSO): δ 165.9, 163.3, 128.9, 128.6, 123.4, 123.3
119.9, 119.4, 108.3, 107.0, 61.1, 58.7, 43.9, 42.8. Mass spec
(ESI positive ion): m/z: 362 ([Co(cat)tren]+). Anal. Required for
C16H27ClCoN4O7.5: C, 39.24, H, 5.56, N, 11.44%. Found: C,
39.17, H, 5.50, N, 11.46%.
Results and discussion
Crystal structures
The bond lengths and angles observed in the solid-state struc-
tures of the complexes (Table 2) are commensurate with those of
similar compounds described in the literature.21,25,41,42 ORTEP43
representations of [Co(naac)tpa](ClO4)2 and [Co(naac)tren]-
(ClO4)2 are shown in Fig. 2. For all the tpa complexes with the
exception of [Co(Clacac)tpa](ClO4)2, the bond distance from the
This journal is © The Royal Society of Chemistry 2012 Dalton Trans., 2012, 41, 11293–11304 | 11299
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tertiary amine to the metal centre is longer (1.9421(17)–1.958(5)
Å) than the Co–N lengths associated with the pyridyl moieties
(1.915(5)–1.939(3) Å). In contrast, the Co–N bond lengths of
the tertiary and equatorial amines of the tren ligands (1.925(3)–
1.9521(16) Å) are generally shorter than the Co–N lengths for
the axial amines (1.9509(11)–1.9669(16) Å). Crystal packing is
generally dominated by hydrogen bonding in the tren-containing
species and π–π interactions in the tpa-containing complexes.
NMR studies indicate that the unsymmetric β-diketone deriva-
tives synthesised here exist as only one isomeric form in solution
despite two isomers being possible. The crystallographic data
suggests in all cases that the bulkier β-diketone substituent is cis
to the tertiary amine of the tripodal ligand. While this would be
expected to be the more sterically favoured isomer for the tpa
derivatives, this reasoning can not be extended to the tren deriva-
tives, where the steric preference between the cis and trans
isomers is unlikely to be of significance.
In contrast to the β-diketone derivatives, the NMR data of
several of the hydroxamic acid complexes showed that more
than one isomeric form is present in solution. While the Co–O
lengths for the β-diketone moieties are similar in the tpa and tren
derivatives, the substitution of tpa for tren affects these bond
lengths for the hydroxamic acid complexes.
In these derivatives, the Co–O bond lengths are uniformly
longer in the tren hydroxamic acid complexes (1.894(2)–1.906(4)
Å) than in the tpa hydroxamic acid structures described here
(1.854(2)–1.867(3) Å). The other bond lengths are commensu-
rate with previously observed structures, and the carbonyl CvO
bond lengths observed in the solid state25 support the hydroxi-
mate/hydroxamate assignments made from NMR, MS and
elemental data. The CIFs can be found in the ESI.†
pKa studies
The absorption, excitation and emission spectra of nhaH have
been previously described.44 While the absorption spectra are
unchanged on varying pH, the fluorescence of nhaH was elimi-
nated when the pH was raised (Fig. 3). These results suggest the
pKa of the hydroxamic acid is approximately 9.0, which is
within the range observed for other hydroxamic acids.45
For the complexes studied here, both the hydroxamate (mono-
anionic) and hydroximate (dianionic) forms could be isolated.
Interconversion between the two is associated with addition or
removal respectively of the N–H proton which gives rise to a dis-
tinctive colour change that can be followed by UV-vis
Table 2 Bond length (Å) comparison between the cobalt-tren and cobalt-tpa complexes with different ancillary ligands
Tren complexes
Structure Co–N(1) Co–N(2) Co–N(3) Co–(N4) Co–O(1) Co–O(2)
[Co(naac)tren](ClO4)2 1.9502(11) 1.9380(11) 1.9620(12) 1.9509(11) 1.8901(9) 1.8918(9)
1.9462(11) 1.9465(11) 1.9656(12) 1.9557(11) 1.8850(9) 1.8909(9)
1.9467(11) 1.9477(11) 1.9659(12) 1.9562(11) 1.8840(9) 1.8877(9)
1.9482(11) 1.9396(11) 1.9594(12) 1.9516(11) 1.8906(9) 1.8905(9)
[Co(bha)tren](ClO4)2 1.925(3) 1.940(3) 1.962(3) 1.949(3) 1.894(2) 1.903(2)
[Co(aha)tren](ClO4)2 1.936(4) 1.945(4) 1.964(4) 1.958(4) 1.906(4) 1.899(3)
[Co(bzac)tren](ClO4)2 1.942(7) 1.942(7) 1.956(8) 1.954(7) 1.879(6) 1.882(6)
[Co(acac)tren](ClO4)2 1.927(6) 1.937(6) 1.961(10) 1.974(10) 1.899(6) 1.902(5)
[Co(nha-H)tren]ClO4 1.9389(16) 1.9521(16) 1.9668(16) 1.9669(16) 1.9006(14) 1.9029(13)
Tpa complexes
Structure Co–N(1) Co–N(2) Co–N(3) Co–(N4) Co–O(1) Co–O(2)
[Co(Clacac)tpa](ClO4)2 1.928(11) 1.837(9) 1.916(8) 1.945(8) 1.894(7) 1.933(8)
1.82(2) 1.73(2) 1.908(7) 1.945(7) 1.94(2) 2.06(2)
[Co(nha-H)tpa](ClO4) 1.956(3) 1.939(3) 1.918(3) 1.921(3) 1.854(2) 1.867(3)
[Co(bzac)tpa](ClO4)2 1.944(2) 1.935(2) 1.928(3) 1.929(3) 1.872(2) 1.886(2)
[Co(cat)tpa](ClO4) 1.946(5) 1.916(4) 1.915(5) 1.927(5) 1.892(4) 1.897(4)
1.958(5) 1.918(4) 1.919(5) 1.926(5) 1.872(4) 1.891(4)
[Co(naac)tpa](ClO4)2 1.9421(17) 1.9296(18) 1.9211(19) 1.9316(19) 1.8739(15) 1.8857(15)
[Co(acac)tpa](ClO4)2 1.9510(17) 1.9304(17) 1.9240(18) 1.9281(18) 1.8847(14) 1.9027(14)
Fig. 2 ORTEP representations of [Co(naac)tpa](ClO4)2 (top) and [Co-
(naac)tren](ClO4)2 (bottom).
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spectrometry (Fig. 4 and 5). As shown in Table 3, the pKa values
for the cobalt-tpa complexes are significantly lower than for the
equivalent cobalt-tren complexes and the aromatic hydroxamic
acids (5.3) had significantly lower pKa values than for the ali-
phatic aha derivatives (6.2 and 7.0 for [Co(aha)tpa](ClO4)2, and
[Co(nha)tpa](ClO4)2 respectively).
The shift from hydroxamate to hydroximate not only changes
the formal charge of the complex, but also greatly influences the
reduction potential (discussed further below). With the correct
choice of ligand and complex charge, this can be potentially
exploited to incorporate two methods of tumour targeting in the
one complex, and studies along these lines have begun.27
Electrochemistry
The electrochemistry results for all compounds are shown in
Table 4. The reduction potentials of all tren compounds are sig-
nificantly more negative than for the comparable tpa complexes
of the same ancillary ligands subtype. This stems from the differ-
ences in bonding of the pyridyl and amine nitrogen donors with
the metal centres. While amines can only undergo σ interactions
with metal centres, pyridyl rings are capable of acting as
π-acceptors47 and the relationship between π-acceptor capabili-
ties and reduction potential is well established.48
The greater irreversibility observed for the tren complexes is
also related to their more negative reduction potentials (Fig. 6).
Previous studies have qualitatively revealed that an increased rate
Fig. 3 Comparison between the fluorescence emission of nhaH at
different pHs. Studies were performed in methanol–water (1 : 1) with
excitation at 280 nm.
Fig. 4 UV-vis spectra of [Co(bha)tpa](ClO4)2 as the pH is increased
from 2.0 to 8.0. Studies were performed at approximately 1 mM in
DMF–water (1 : 1) with 20 mM buffer (citrate/phosphate/triethylamine).
Fig. 5 pH titration curve (pH vs. λmax) for [Co(bha)tpa](ClO4)2.
Studies were performed at approximately 1 mM in DMF–water (1 : 1)
with 20 mM buffer (citrate/phosphate/triethylamine).
Table 3 pKa values obtained for hydroxamic acids and their
complexes
Ligand Free ligand Cobalt-tren complex Cobalt-tpa complex
ahaH 9.446 8.5 7.0
bhaH 8.846 7.7 5.3
nhaH 9.1 7.8 6.2
Table 4 Reduction potentials of cobalt complexes. Scans performed in
DMF and 80% DMF are referenced to Fc/Fc+. Those performed in H2O
are referenced to Ag/AgCl
Compound
DMF
Epc Epa
DMF
Epc
(80%)
Epa
H2O
Epc Epa
[Co(acac)tpa](ClO4)2 −605 −465 −600 −455 — —
[Co(Clacac)tpa](ClO4)2 −520 −315 −550 −380 — —
[Co(bzac)tpa](ClO4)2 −560 −415 −570 −400 — —
[Co(naac)tpa](ClO4)2 −560 −420 −570 −400 — —
[Co(nha)tpa](ClO4)2 −740 —a −670 — — —
[Co(nha-H)tpa](ClO4) −1385 — −840 — — —
[Co(bha)tpa](ClO4)2 −720 — nrb — nr —
[Co(bha-H)tpa](ClO4) −1350 — −850 — −770 —
[Co(aha)tpa](ClO4)2 −800 — −680 — −520 —
[Co(aha-H)tpa](ClO4)2 −1400 — −880 — −835 —
[Co(cat)tpa](ClO4) −1120 −910 −1040 — — —
[Co(acac)tren](ClO4)2 −978 — −940 — −685 —
[Co(bzac)tren](ClO4)2 −960 — −910 — −510 —
[Co(naac)tren](ClO4)2 −952 — −910 — −450 —
[Co(nha)tren](ClO4)2 −1150 — −1040 — −570 —
[Co(nha-H)tren](ClO4) −1650 — −1380 — −860 —
[Co(bha)tren](ClO4)2 −1130 — −970 — −530 —
[Co(bha-H)tren](ClO4) −1630 — −1370 — −830 —
[Co(aha)tren](ClO4)2 −1210 — −1050 — −620 —
[Co(aha-H)tren](ClO4) −1720 — −1400 — −930 —
[Co(cat)tren](ClO4) −1420 — −1240 — −780 —
a ‘—’ indicates no peak observed. b ‘nr’ indicates results were not
reproducible.
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of solvolysis and thus hindrance of the reoxidation wave occurs
with decreased reduction potential.49 In addition, the π back-
bonding interactions between the metal centre and tpa potentially
result in decreased ligand lability,50 which may contribute to the
greater reversibility observed in the reduction of the tpa
complexes.
Within a particular tripodal ligand class, the reduction poten-
tials of the complexes corresponded strongly with the ancillary
oxygen ligand in the order β-diketone > hydroxamate > catechol
> hydroximate. This is consistent with the doubly deprotonated
ligands conferring a greater electron density onto the metal
centres than the comparable monoanionic oxygen bidentates.
The presence of an electron-withdrawing chloride group in the
[Co(Clacac)tpa](ClO4)2 derivative made the reduction potential
significantly more positive. This is commensurate with previous
studies of cobalt(III) β-diketonato complexes which found direct
correlations between reduction potentials and the Hammett σ
parameters of the substituents on the β-diketone ligands.51
The pH of the solutions used for the electrochemistry scans
also influenced the cyclic voltammetry results, particularly for
the cobalt–hydroxamic acid complexes. Increasing the pH above
the pKa values of the hydroxamate complexes resulted in depro-
tonation and hence formation of the hydroximate in situ. This
corresponded with a shift to the more negative reduction poten-
tials associated with the doubly deprotonated (hydroximate)
ligands. The reduction potentials of cobalt–hydroximate com-
plexes prepared in situ by this manner were indistinguishable
from those of freshly prepared cobalt–hydroximate solutions. For
the catechol and diketone derivatives, no shift in reduction
potential was observed with altered pH. However, an increase in
the current magnitude in the anodic return wave was observed at
higher pH values, presumably because high pH maintains the
free ancillary ligand that forms under reduction in a deprotonated
form, which facilitates reoxidation of the cobalt complexes.
Reduction with ascorbic acid
As the naphthyl moieties are fluorescent, all the complexes con-
taining naphthyl derivatives were tested for reduction with ascor-
bate by fluorimetry (full details in experimental data).
For all cobalt complexes the fluorescence intensity was less
than 1% of that observed for the equivalent concentration of free
ligand, which could be related to deprotonation of the ligands
upon binding to cobalt, or more directly to the presence of the
cobalt which has previously been reported to quench fluor-
escence by electron or energy exchange mechanisms.52
When ten equivalents of ascorbic acid were added to the sol-
ution and the fluorescence was measured at a variety of time
points over 24 hours, only [Co(naac)tpa](ClO4)2 demonstrated
any increase in fluorescence after 24 hours, which is consistent
with the reduction potentials for most of the complexes being
too negative to allow reduction by ascorbate. In contrast, the
[Co(naac)tpa](ClO4)2 solution showed a steady increase in fluor-
escence such that after 24 hours it was approximately 40% of the
intensity of the comparable reference solution of the ligand
which is consistent with reduction and ligand dissociation under
these conditions.
Cytotoxicity
As with the fluorescence work, all naphthyl derived ligands and
their associated compounds were tested for cytotoxicity. None of
the complexes or their ligands were particularly cytotoxic
(Table 5) with the exception of the free tpa ligand. Similar to
what has previously been observed, the cytotoxicity of the free
tpa ligand was far greater than that of any of the tpa com-
plexes,53 which suggests that the toxicity of the tpa ligand is
masked by coordination to a metal centre, and this is maintained
in biological environments. The naacH free ligand was shown to
be mildly cytotoxic under both hypoxic and normoxic conditions
(IC50 74 ± 3 and 60 ± 1.6 μM respectively) and there was no
statistically significant difference between the cytotoxicity of the
free ligand and the cytotoxicity of the respective tpa complex
[Co(naac)tpa](ClO4)2 (IC50 74 ± 4 and 66 ± 3 μM under hypoxic
or normoxic condition respectively). In contrast, [Co(naac)tren]-
(ClO4)2 has far lower cytotoxicity than free naacH under both
hypoxic and normoxic conditions. The above results indicated
that the cytotoxicity of the naacH ligand is masked upon binding
to the cobalt-tren derivative while the behaviour of the cobalt-tpa
derivative is indistinguishable from that of free ligand in
solution. This is despite both compounds showing no
Fig. 6 Comparison between the cyclic voltammograms of [Co(acac)-
tpa](ClO4)2 and [Co(acac)tren](ClO4)2. Scans were performed in DMF
at 100 mV s−1.
Table 5 IC50 (μM) of the compounds used in this study in human
DLD-1 colon carcinoma cells
Compound Normoxia Hypoxia
tren >200 >200
tpa 5 ± 0.3 5 ± 0.2
nhaH >200 >200
naacH 60 ± 1.6 74 ± 3
catH2 127 ± 7 113 ± 4
[CoCl2tren]ClO4 >200 >200
[CoCl2tpa]ClO4 >200 >200
[Co(nha-H)tren]ClO4 >200 >200
[Co(nha-H)tpa]ClO4 >200 >200
[Co(naac)tren](ClO4)2 >200 >200
[Co(naac)tpa](ClO4)2 66 ± 3 74 ± 4
[Co(cat)tren]ClO4 >200 >200
[Co(cat)tpa]ClO4 >200 >200
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degradation by NMR over 48 h in aqueous solution. Unfortu-
nately, the [Co(naac)tpa](ClO4)2 complex did not show any
hypoxic selectivity and it was not possible to ascertain whether
any of the complexes are hypoxia selective due to their low
cytotoxicity.
Conclusions
Cobalt complexes that are selectively reduced under hypoxic
conditions have been investigated as chaperones for prodrugs. In
this study, a clear correlation between reduction potential, ligand
dissociation under ascorbic acid challenge, and cytotoxicity was
observed. Specifically, the free naacH ligand and [Co(naac)tpa]-
(ClO4)2 show comparable cytotoxicities, both under hypoxic and
normoxic conditions, while all other complexes demonstrate
higher IC50 values for the cobalt complexes when compared to
their respective free ligands. The cyotoxicity data supports the
notion that [Co(naac)tpa](ClO4)2 quickly dissociates and loses
its naacH ligand in solution while [Co(naac)tren](ClO4)2, and
the other complexes investigated do not. This is commensurate
with [Co(naac)tpa](ClO4)2 having a significantly less negative
reduction potential (−560 mV Epc in DMF vs. Fc+/Fc) than any
of the other complexes examined in cytotoxicity studies (−970
to −1650 mV in DMF vs. Fc+/Fc), as well as being the only
complex to display appreciable reduction by ascorbic acid over
24 hours. Together, these results support the correlation between
reduction potential and ligand dissociation.
The ability to manipulate formal complex charge to influence
biological behaviour has also been investigated for cobalt com-
plexes.26,27 The intrinsic acid properties of the hydroxamic acid
make them potentially useful for this purpose. The results of this
study demonstrate that the pKa of the hydroxamate–hydroximate
transition can be influenced by the ancillary ligand as well as the
substituents on the hydroxamic acid and that the reduction poten-
tial is also affected. As such, cobalt hydroxamic acid complexes
can potentially target tumours by two distinct mechanisms. In
the first instance, protonation of the hydroxamic acid changes the
formal charge of the cobalt complex and thus also changes its
cellular uptake characteristics, as has previously been shown in
3D cell culture by Yamamoto.27 Additionally, the protonation of
hydroxamic acid allows reduction of the cobalt metal centre to
occur at significantly more positive potentials and thus reduction
is considerably more facile under acidic conditions. The combi-
nation of these two elements suggest that cobalt hydroxamic acid
complexes can be designed such that under the acidic and
hypoxic conditions found in many tumours; the hydroxamic acid
is primarily in the hydroxamate form, the cobalt complex for-
mally neutral and the reduction potential relatively positive, all
of which favour high uptake and/or ligand dissociation. In con-
trast, the same complexes under the more alkaline, normoxic
conditions of normal tissue would exist with the hydroxamic
acid primarily in hydroximate form, the cobalt complex formally
negatively charged and the reduction potential more negative,
favouring low cellular uptake and lower ligand dissociation. The
combination of these two modes of selectively can thus be
exploited to significantly reduce toxic side-effects and, as such,
development of novel cobalt complexes based on these criteria
has begun.
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Abbreviations
acacH acetylacetone
ahaH acetohydroxamic acid
bhaH benzohydroxamic acid
bzacH 1-phenyl-1,3-butanedione
ClacacH 3-chloro-2,4,-pentanedione
haH generic hydroxamic acid
HCR hypoxic cell response
naacH 1-methyl-3-(2-naphthyl)propane-1,3-dione
nhaH 1-napthylacetohydroxamic acid
TAP tumour activated prodrug
tpa tris-(2-pyridylmethyl)amine
TPZ tirapazamine
tren tris-(2-aminoethyl)amine
trp generic tripodal ligand
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